Axsome Therapeutics Reports Third-Quarter Revenue of $259.7 Million
Revenue rose 51.9% from $171 million a year earlier. Net loss narrowed to $12.9 million from $47.2 million, and diluted loss per share was $(0.25), versus $(0.94) a year earlier.
Axsome Therapeutics reported third-quarter 2026 revenue of $259.7 million, up 51.9% from $171 million a year earlier, while its net loss narrowed to $12.9 million from $47.2 million. Diluted loss per share was $(0.25), compared with $(0.94) in the prior-year quarter.Financial HighlightsBusiness Hig…